Glancy Prongay Seeks To Represent Blood Clot Co. Investors

By Emilie Ruscoe · March 17, 2020, 8:02 PM EDT

Glancy Prongay & Murray LLP on Monday sought to represent a proposed class of investors in a proposed securities fraud class action accusing biotechnology company Portola Pharmaceuticals Inc. of not properly...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Hayden v. Portola Pharmaceuticals, Inc. et al

Case Number

3:20-cv-00367

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 16, 2020